BioClinica ApS: Financial statements 2023
CVR: 41590939
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
BioClinica ApS (CVR 41590939) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -19,274 and a net result of DKK -24,530 compared with DKK -22,672 the year before. Equity in the 2023 report amounted to DKK -95,001.
- Gross Profit
- DKK -19,274
- Profit/Loss
- DKK -24,530
- Equity
- DKK -95,001
- Total Assets
- DKK 54,874
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -19 t. | -25 t. | -95 t. | - |
| 2022 | - | -22 t. | -23 t. | -70 t. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of October 31, 2023, Thomas Patrick Stuckey is registered as director of BioClinica ApS.
BioClinica ApS has published its annual report for 2022. Gross profit came to DKK -22,036, and the net result was DKK -22,672.
As of April 27, 2023, Daniel Scott Braem is registered as adm. dir. of BioClinica ApS.
As of March 28, 2023, Michael John Bonello has stepped down as director of BioClinica ApS.
As of March 15, 2023, Maureen Waters Marchek has stepped down as director of BioClinica ApS.
About BioClinica ApS
BioClinica ApS was a Danish company of the type Anpartsselskab based in København K, founded in 2020. The company has been dissolved on 26 February 2026. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. In 2024, the company reported a gross profit of DKK -63,754 and a net result of DKK -73,479 compared with DKK -24,530 the year before. Equity in the 2024 report amounted to DKK -168,480.